Patterns of Recurrence on Cutaneous Melanoma: A Literature Review

The incidence of melanoma has been dramatically increasing over the last decades. Melanoma is considered to have a high metastatic potential and it can progress via lymphatic vessels or through hematogenous metastasis. Different patterns of recurrence have been described, namely, local, satellite, and in transit metastasis (LCIT), lymphatic metastasis, and systemic metastasis. With a more advanced melanoma stage at diagnosis, there is a higher risk for systemic metastasis in comparison to LCIT; in contrast, early-stage melanoma tends to recur more frequently as LCIT and less commonly as systematic metastasis. The aim of this review was to summarize the patterns of recurrence of cutaneous melanoma, giving the clinician a practical summary for diagnosis, prognosis, and surveillance. There is a knowledge gap of the common patterns of recurrence that needs to be addressed to better identify patients at high risk of disease recurrence and personalize surveillance strategies as well as patient counseling. ABSTRACT

[1]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[2]  Shenmin Zhang,et al.  Prediction of early-stage melanoma recurrence using clinical and histopathologic features , 2022, npj Precision Oncology.

[3]  D. Coit,et al.  Fifty years of progress in surgical oncology: Melanoma , 2022, Journal of surgical oncology.

[4]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. , 2022, European journal of cancer.

[5]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.

[6]  N. Khushalani,et al.  Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better? , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[7]  J. Malvehy,et al.  Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence , 2021, Acta dermato-venereologica.

[8]  B. Oh,et al.  Male sex and Breslow thickness are important risk factors for recurrence of localized melanoma in Korean populations. , 2020, Journal of the American Academy of Dermatology.

[9]  P. Ascierto,et al.  Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. , 2020, The Lancet. Oncology.

[10]  P. Spanheimer,et al.  Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma , 2020, The British journal of surgery.

[11]  A. Masiak,et al.  Long-term Follow-up , 2020, Definitions.

[12]  M. Hendriks,et al.  Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  V. Sondak,et al.  Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival , 2019, Annals of Surgical Oncology.

[14]  J. Larkin,et al.  Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate‐risk cutaneous melanoma , 2019, The British journal of surgery.

[15]  R. Zitsch,et al.  Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients , 2019, Head & neck.

[16]  J. Wayne,et al.  Follow‐up of the melanoma patient , 2018, Journal of surgical oncology.

[17]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[18]  Nooreen Dabbish,et al.  Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. , 2017, Journal of the American College of Surgeons.

[19]  D. Coit,et al.  Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients , 2017, Annals of Surgical Oncology.

[20]  A. Barbour,et al.  Primary cutaneous melanoma of the scalp: Patterns of recurrence , 2017, Journal of surgical oncology.

[21]  S. Rosenberg,et al.  Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients , 2017, Annals of Surgical Oncology.

[22]  A. Haydon,et al.  Metastatic pathways in patients with cutaneous melanoma , 2017, Pigment cell & melanoma research.

[23]  H. Minn,et al.  Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma* , 2016, Acta oncologica.

[24]  J. Hansson,et al.  Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature , 2016, Clinical epidemiology.

[25]  A. Francken,et al.  The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients—Results after 1 Year , 2016, Annals of Surgical Oncology.

[26]  D. O'Leary,et al.  Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy , 2016, Melanoma research.

[27]  A. Hauschild,et al.  Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study , 2015, The British journal of dermatology.

[28]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[29]  J. Cormier,et al.  Long-term follow-up for melanoma patients: is there any evidence of a benefit? , 2015, Surgical oncology clinics of North America.

[30]  Yan Xing,et al.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review , 2012, Melanoma research.

[31]  Andrew Hayen,et al.  Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Coit,et al.  Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Yeh,et al.  Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging , 2009, Annals of Surgical Oncology.

[34]  A. Bleyer,et al.  Malignant melanoma in the first three decades of life: A report from the U.S. Surveillance, Epidemiology and End Results (SEER) Program , 2004 .

[35]  Claus Garbe,et al.  The natural course of cutaneous melanoma , 2004, Journal of surgical oncology.

[36]  C. O'brien,et al.  Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy , 2004, Annals of Surgical Oncology.

[37]  U. Chetty,et al.  A rational approach to melanoma follow‐up in patients with primary cutaneous melanoma , 1999, The British journal of dermatology.

[38]  S. Ariyan,et al.  Data on First Recurrence after Treatment for Malignant Melanoma in a Large Patient Population , 1993, Plastic and reconstructive surgery.

[39]  Samantha Barbour Mbbs,et al.  Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable? , 2014, Annals of Surgical Oncology.

[40]  T. Johnson Guidelines of care for the management of primary cutaneous melanoma. , 2013, Journal of the American Academy of Dermatology.

[41]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[42]  F. Meier,et al.  Metastatic pathways and time courses in the orderly progression of cutaneous melanoma , 2002, The British journal of dermatology.

[43]  U. Ringborg,et al.  Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. , 1999, Acta oncologica.